Evidence map›Paper›PMID 33459147›Full record

ArticlemAbs

Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors.

Adam R Root, Gurkan Guntas, Madan Katragadda, James R Apgar, Jatin Narula, Chew Shun Chang, Sara Hanscom, Matthew McKenna, Jason Wade, Caryl Meade and 38 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

48 authors at 1 institution in 1 country.

Adam R RootBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Gurkan GuntasBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Madan KatragaddaBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
James R ApgarBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.ORCID 0000-0002-4669-0188
Jatin NarulaBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Chew Shun ChangBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Sara HanscomBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Matthew McKennaBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Jason WadeBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Caryl MeadeBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Weijun MaBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Yongjing GuoBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Yan LiuBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Weili DuanBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Claire HendershotBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Amy C KingBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Yan ZhangBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Eric SousaBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Amy TamBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Susan BenardBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Han YangBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Kerry KelleherBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Fang JinBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Nicole Piche-NicholasBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.ORCID 0000-0003-0695-7965
Sinead E KeatingBioMedicine Design, Pfizer Inc ., Dublin, IE, USA.
Fernando NarciandiBioMedicine Design, Pfizer Inc ., Dublin, IE, USA.
Rosemary Lawrence-HendersonBioMedicine Design, Pfizer Inc ., Andover, MA, USA.
Maya AraiBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Wayne R StochajBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Kristine SvensonBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Lidia MosyakBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Khetemcnee LamBioMedicine Design, Pfizer Inc ., Andover, MA, USA.
Christopher FrancisBioMedicine Design, Pfizer Inc ., Andover, MA, USA.
Kimberly MarquetteBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Liliana WroblewskaBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
H Lily ZhuBioMedicine Design, Pfizer Inc ., Andover, MA, USA.
Alfredo Darmanin SheehanBioMedicine Design, Pfizer Inc ., Dublin, IE, USA.
Edward R LaVallieBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Aaron M D'AntonaBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Alison BettsBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Lindsay KingBioMedicine Design, Pfizer Inc ., Andover, MA, USA.
Edward RosfjordOncology Research & Development, Pfizer Inc ., Pearl River, NY, USA.
Orla CunninghamBioMedicine Design, Pfizer Inc ., Dublin, IE, USA.ORCID 0000-0002-3888-9541
Laura LinBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Puja SapraOncology Research & Development, Pfizer Inc ., Pearl River, NY, USA.
Lioudmila TchistiakovaBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Divya MathurOncology Research & Development, Pfizer Inc ., Pearl River, NY, USA.
Laird BloomBioMedicine Design, Pfizer Inc ., Cambridge, MA, USA.
Pfizer (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report here the discovery and optimization of a novel T cell retargeting anti-GUCY2C x anti-CD3ε bispecific antibody for the treatment of solid tumors. Using a combination of hybridoma, phage display and rational design protein engineering, we have developed a fully humanized and manufacturable CD3 bispecific antibody that demonstrates favorable pharmacokinetic properties and potent

Indexed as

AnimalsAntibodies, BispecificCD3 ComplexCell Line, TumorFemaleHumansHybridomasImmunotherapy, AdoptiveMacaca fascicularisMiceMice, Inbred BALB CNeoplasmsProtein EngineeringReceptors, EnterotoxinSingle-Chain AntibodiesT-LymphocytesAntibodies, BispecificCD3 ComplexCD3E protein, humanGUCY2C protein, humanReceptors, EnterotoxinSingle-Chain Antibodiesantibody engineeringantibody optimizationdevelopabilityGuanlyate cyclase 2c (GCC)GUCY2Chigh-throughput protein productionimmuno-oncologyPF-07062119T-BsAbT cell bispecificT cell retargeting

Identifiers

PMID33459147
PMCPMC7833764
OpenAlexW3123815925

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.